Nursing
December 1, 2025
Rebecca Ann Ivory, Kathryn M. Pate, Brentyn M Jones et al.
Major depressive disorder (MDD) affects approximately 332 million people worldwide. Among those diagnosed with MDD, approximately 53% receive pharmacologic treatment, such as ketamine. Nurses must be knowledgeable about ketamine and other emerging, effective behavioral health therapies used to treat chronically depressed mood and acute suicidal ideation. This article outlines the best nursing...
EClinicalMedicine
December 1, 2025
Tyler S Kaster, Yi Dai, Fidel Vila-Rodriguez et al.
5 citations
Repetitive transcranial magnetic stimulation (rTMS) and intranasal esketamine are effective treatment options for treatment-resistant depression (TRD) that have not been directly compared. We aimed to compare the effectiveness of rTMS, intranasal esketamine, and pharmacotherapy for TRD using data from two randomised clinical trials (RCTs). This secondary analysis of individual patient data...
Journal of psychosomatic obstetrics and gynaecology
December 1, 2025
Yan Shang, Siyuan Li, Qin Zheng et al.
8 citations
To assess the impact of low-dose intravenous esketamine on postpartum depression scores in women undergoing cesarean section. In a randomized, double-blind, placebo-controlled trial, 186 women aged 20-50 years receiving epidural anesthesia for cesarean section were divided into three groups: Group A (0.25 mg/kg esketamine intraoperatively + esketamine in PCIA), Group B (0.25 mg/kg esketamine...
Dialogues in Clinical Neuroscience
December 1, 2025
Ivona-Maria Tudorancea, Gabriela-Dumitrita Stanciu, Carla Torrent et al.
4 citations
The global population is ageing rapidly, with the number of individuals aged 60 and older reaching 1 billion in 2019 and expected to double by 2050. As people age, neuropsychological health often deteriorates, leading to a higher prevalence of age-related depression. Symptoms may include anxiety, apathy, mood instability, sadness, and, in severe cases, suicidal thoughts. Depression in the...
Journal for Specialists in Pediatric Nursing
November 30, 2025
Cara Gallegos, V. Toly, Matthew Bailey
PURPOSE Parents of children with medical complexity (CMC) frequently experience challenges with family management and depression. The purpose of the study was to provide preliminary feasibility, usage, acceptability, and efficacy data following a trial of mindfulness app use in parents of a CMC. DESIGN AND METHODS In this single-arm intervention pilot study, parents were asked to use a...
Journal of Education, Health and Sport
November 29, 2025
Natalia Dudziak, Zuzanna Drozd, Bartosz Niemiec et al.
Background. Major depressive disorder affects 20% of the global population, with treatment-resistant depression in 10-30% of cases. Patients with acute suicidal ideation need immediate intervention, yet conventional antidepressants require weeks to work. Esketamine offers rapid symptom reduction through NMDA receptor antagonism. Aim. To systematically review current evidence on efficacy and...
BMC Medicine
November 28, 2025
Florian Naudet, Claude Pellen, Liviu A Fodor et al.
5 citations
In 2019, the FDA and EMA approved intranasal esketamine for treatment-resistant depression (TRD). The current study re-evaluated its efficacy and safety. This registered report presents a systematic review and individual patient data (IPD) meta-analysis of double-blind, randomised, placebo-controlled trials (RCTs) assessing intranasal esketamine for TRD. Two reviewers independently screened...
Journal of Psychiatric Research
November 27, 2025
Tor-Morten Kvam, Ivar W Goksøyr, Joanna Róg et al.
3 citations
BACKGROUND: Major depressive disorder (MDD) is a leading cause of global disability, and current treatments often fail to provide sustained effectiveness. MDMA-assisted therapy (MDMA-AT) is a promising treatment for MDD. However, the long-term effects are not known. OBJECTIVES: To examine the long-term effects of MDMA-AT for MDD. METHODS: Twelve participants with MDD and an ongoing moderate to...
Issues of Rehabilitation Orthopaedics Neurophysiology and Sport Promotion – IRONS
November 26, 2025
Zofia Maria Kiestrzyn, Mart Kubik, Aleksandra Kałużna et al.
Depressive disorder is a widespread psychological condition. It affects approximately 5% of adults globally. Untreated depression can compromise the quality of life in all its aspects, leading to deterioration of physical health or even suicide. Currently, the recommended treatment is pharmacological therapy, however, not all patients respond to traditional methods, and drug treatment is...
Journal of Affective Disorders
November 22, 2025
Carlos Trenado, Erich Seifritz, Sebastian Olbrich et al.
4 citations
Ketamine and its enantiomer esketamine are NMDA receptor antagonists that have shown consistent antidepressant effects in major depression disorder (MDD). These effects suggest an active role of glutamate in the pathophysiology of depression. It has been hypothesized that acute increase of glutamate neurotransmission in the prefrontal cortex following treatment with (es)ketamine leads to...